$WGS News

GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis

GeneDx Plans To Enhance Its Genome Testing Portfolio With Long-Read Whole Genome Sequencing

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

GeneDx Advances Clinical Adoption Of Genomic Medicine With 27 Abstracts At American Society Of Human Genetics 2026

GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026

GeneDx To Present New Results At International Consortium On Newborn Sequencing For Its Genomic Newborn Screening

GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care

Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83

GeneDx Stock Is Down 30% In Last 1 Year, Can It Climb Again in 2027?

GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

GeneDx Partners With Beren Therapeutics To Launch The NPC GenomeComplete Sponsored Testing Program For Niemann-Pick Disease Type C

GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

GeneDx Announces New Data Published In Genetics In Medicine Demonstrating First‑Tier Rapid Genome Sequencing Improves Diagnostic Rates, Patient Outcomes, And Operational Efficiency In Pediatric Care

Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?

GeneDx: Why I Think The Worst Is Behind The Business

GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy

GeneDx (WGS) Q2 2026 Earnings Call Transcript

GeneDx Holdings (WGS) Is Up 18.4% After Reaffirming 2026 Outlook And Raising Equity From Blackstone